Introduction:

Exosomes have emerged as a novel alternative delivery system for transporting small molecules. Tumor-derived exosomes (TEXs) possess anti-cancer properties and serve as natural carriers of microRNAs. Using this knowledge as a foundation, the current study evaluated the efficacy of delivering a miR-211 mimic via B16F10 cell-derived exosomes to block the growth and development of a melanoma cell line.

Material and methods:

After exposing B16F10 cultured cells to serum-free media for 24 hours, we collected the supernatant. Subsequently, we purified the exosomes from the supernatant using a commercial kit. Scanning electron microscopy, transmission electron microscopy, dynamic light scattering, Western blot, and bicinchoninic acid protein assay were used to characterize exosomes. Following that, miR-211 mimic was loaded into exosomes (termed TEXomiR) via a modified calcium chloride procedure. The assessment of miR-211a loading efficiency into exosomes was conducted by analyzing its relative expression. MTT, annexin V/PI, and quantitative real-time polymerase chain reaction were used to measure the proliferation, apoptosis and relative expression of miR-211 target genes, respectively.

Results:

Our study showed that the exosomes can deliver miR-211 mimic efficiently. The treatment of B16F10 cells with miR-211-enriched TEX downregulated miR-211 target genes, including brain-specific homeobox, vascular endothelial growth factor, and transforming growth factor- receptor. The results indicated the antiproliferative effect of TEXomiR as time-dose-dependent. The flow cytometry evaluation showed that TEXomiR could induce the apoptosis of B16F10 cells.

Conclusions:

Our data indicated that exosomes can be suitable carriers for miR-211 mimic. Moreover, TEXomiR via anti-cancer effects could inhibit the progression of melanoma cancer.